Post by Simbec-Orion

Phase I success isn’t about ticking boxes, it’s about making the right decisions early. From clinical intent and PK/PD strategy to CMC readiness and study design, the groundwork for first-in-human trials is laid long before dosing begins. We’ve pulled together key considerations that can help biotechs reduce risk and generate more meaningful Phase I data. Take a look at our latest insights below. #PhaseI #Biotech #DrugDevelopment #ClinicalResearch